Incyte's stock rallies 9% after company says to buy back $1.67 billion of its own stock in Dutch auction tender
By Ciara Linnane
Biotech says board has approved share buyback authorization of up to $2 billion
Biotech Incyte Corp. said Monday its board has approved a share buyback of up to $2 billion and the company has commenced a modified Dutch auction tender for up to $1.67 billion worth.
The news sent the stock up 9% in early trade.
The offer "reflects our confidence in the future outlook of our business, the strength of our commercial product portfolio and our clinical development pipeline and Incyte's long-term value," Chief Executive Hervé Hoppenot said in prepared remarks.
The tender offer will be priced at no greater than $60 a share, which compares with the stock's (INCY) closing price Friday at $53.06.
In addition, the company has an agreement with Julian C. Baker, a member of its board, Felix J. Baker, and units affiliated with the two including funds advised by Baker Bros. Advisors LP, to repurchase up to $328 million of the company's common stock.
That will allow the Baker entities to maintain their current stake of about 16.4% of Incyte's outstanding stock. The Baker entities will pay the same price as in the tender offer.
The stock is down 8% in the year to date, while the S&P 500 SPX has gained 9.5%.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-13-24 1016ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks